Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 1634730, 13 pages
http://dx.doi.org/10.1155/2016/1634730
Research Article

Rapid Identification of Potential Drugs for Diabetic Nephropathy Using Whole-Genome Expression Profiles of Glomeruli

National Clinical Research Center of Kidney Diseases, Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210016, China

Received 23 October 2015; Revised 25 January 2016; Accepted 8 February 2016

Academic Editor: Gianluigi Zaza

Copyright © 2016 Jingsong Shi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y.-M. Sun, Y. Su, J. Li, and L.-F. Wang, “Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy,” Biochemical and Biophysical Research Communications, vol. 433, no. 4, pp. 359–361, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Lv, Z. Chen, G. Hu, and Q. Li, “Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives,” Drug Discovery Today, vol. 20, no. 3, pp. 332–346, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Lamb, E. D. Crawford, D. Peck et al., “The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease,” Science, vol. 313, no. 5795, pp. 1929–1935, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Zhong, E. Y. Chen, R. Liu et al., “Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase,” Journal of the American Society of Nephrology, vol. 24, no. 5, pp. 801–811, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. T. W. C. Tervaert, A. L. Mooyaart, K. Amann et al., “Pathologic classification of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 21, no. 4, pp. 556–563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Tippmann, “Programming tools: adventures with R,” Nature, vol. 517, no. 7532, pp. 109–110, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. R. C. Gentleman, V. J. Carey, D. M. Bates et al., “Bioconductor: open software development for computational biology and bioinformatics,” Genome Biology, vol. 5, no. 10, article R80, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. R. A. Irizarry, B. Hobbs, F. Collin et al., “Exploration, normalization, and summaries of high density oligonucleotide array probe level data,” Biostatistics, vol. 4, no. 2, pp. 249–264, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. M. E. Ritchie, B. Phipson, D. Wu et al., “Limma powers differential expression analyses for RNA-sequencing and microarray studies,” Nucleic Acids Research, vol. 43, no. 7, p. e47, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Method, vol. 25, no. 4, pp. 402–408, 2001. View at Google Scholar
  11. G. Feng, P. Du, N. L. Krett et al., “A collection of bioconductor methods to visualize gene-list annotations,” BMC Research Notes, vol. 3, article 10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. F. Navarro-Gonzalez, C. Mora-Fernandez, M. Muros de Fuentes et al., “Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy,” Nature Reviews Nephrology, vol. 7, no. 6, pp. 327–340, 2011. View at Publisher · View at Google Scholar
  13. M. Kato and R. Natarajan, “Diabetic nephropathy—emerging epigenetic mechanisms,” Nature Reviews Nephrology, vol. 10, no. 9, pp. 517–530, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. H. Han, H. J. Moon, B. R. You, and W. H. Park, “The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH,” Oncology Reports, vol. 22, no. 1, pp. 215–221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Pujols, L. Fernández-Bertolín, M. Fuentes-Prado et al., “Proteasome inhibition reduces proliferation, collagen expression, and inflammatory cytokine production in nasal mucosa and polyp fibroblasts,” The Journal of Pharmacology and Experimental Therapeutics, vol. 343, no. 1, pp. 184–197, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Shrivastava, P. Kulkarni, D. Thummuri et al., “Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells,” Apoptosis, vol. 19, no. 7, pp. 1148–1164, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Ginzburg, K. V. Golovine, P. B. Makhov, R. G. Uzzo, A. Kutikov, and V. M. Kolenko, “Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells,” Prostate, vol. 74, no. 2, pp. 177–186, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Tanaka, Y. Nomura, A. Matsuda, K. Ohmori, and H. Matsuda, “Mast cells function as an alternative modulator of adipogenesis through 15-deoxy-delta-12, 14-prostaglandin J2,” American Journal of Physiology-Cell Physiology, vol. 301, no. 6, pp. C1360–C1367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. N. V. Gopal, T. S. Arora, and M. W. Van Dyke, “Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated,” Chemistry & Biology, vol. 14, no. 7, pp. 813–823, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S.-J. Park, F. Ahmad, A. Philp et al., “Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases,” Cell, vol. 148, no. 3, pp. 421–433, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S.-M. Maira, F. Stauffer, C. Schnell, and C. García-Echeverría, “PI3K inhibitors for cancer treatment: where do we stand?” Biochemical Society Transactions, vol. 37, part 1, pp. 265–272, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. K. I. Woroniecka, A. S. D. Park, D. Mohtat, D. B. Thomas, J. M. Pullman, and K. Susztak, “Transcriptome analysis of human diabetic kidney disease,” Diabetes, vol. 60, no. 9, pp. 2354–2369, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Hokama, S. Oka, J. Leon et al., “Altered expression of diabetes-related genes in Alzheimer's disease brains: the Hisayama study,” Cerebral Cortex, vol. 24, no. 9, pp. 2476–2488, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. C. C. Faria, S. Agnihotri, S. C. Mack et al., “Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma,” Oncotarget, vol. 6, no. 25, pp. 21718–21729, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. H.-H. Parving, “Diabetic nephropathy: prevention and treatment,” Kidney International, vol. 60, no. 5, pp. 2041–2055, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Schmid, A. Boucherot, Y. Yasuda et al., “Modular activation of nuclear factor-κB transcriptional programs in human diabetic nephropathy,” Diabetes, vol. 55, no. 11, pp. 2993–3003, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. X. Wang, J. Liu, J. Zhen et al., “Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy,” Kidney International, vol. 86, no. 4, pp. 712–725, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. Q. Lu, Y. Zhai, Q. Cheng et al., “The Akt-FoxO3a-manganese superoxide dismutase pathway is involved in the regulation of oxidative stress in diabetic nephropathy,” Experimental Physiology, vol. 98, no. 4, pp. 934–945, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Yamaguchi, H. Matsuda, H. Zhang et al., “Adipogenic effects of piperlonguminine in 3T3-L1 cells and plasma concentrations of several amide constituents from Piper chaba extracts after treatment of mice,” Journal of Natural Medicines, vol. 68, no. 1, pp. 74–82, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. S. A. Nabi, R. B. Kasetti, S. Sirasanagandla, T. K. Tilak, M. V. J. Kumar, and C. A. Rao, “Antidiabetic and antihyperlipidemic activity of Piper longum root aqueous extract in STZ induced diabetic rats,” BMC Complementary and Alternative Medicine, vol. 13, article 37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Li, X. Wen, B. C. Spataro, K. Hu, C. Dai, and Y. Liu, “Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-γ agonists,” Journal of the American Society of Nephrology, vol. 17, no. 1, pp. 54–65, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Wang, F. Liu, and N. Chen, “Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists attenuate the profibrotic response induced by TGF-β1 in renal interstitial fibroblasts,” Mediators of Inflammation, vol. 2007, Article ID 62641, 7 pages, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. C. West and R. W. Johnstone, “New and emerging HDAC inhibitors for cancer treatment,” The Journal of Clinical Investigation, vol. 124, no. 1, pp. 30–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. E. A. Olsen, Y. H. Kim, T. M. Kuzel et al., “Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma,” Journal of Clinical Oncology, vol. 25, no. 21, pp. 3109–3115, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Duvic, R. Talpur, X. Ni et al., “Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL),” Blood, vol. 109, no. 1, pp. 31–39, 2007. View at Publisher · View at Google Scholar
  36. R. E. Gilbert, Q. Huang, K. Thai et al., “Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor,” Kidney International, vol. 79, no. 12, pp. 1312–1321, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Advani, Q. Huang, K. Thai et al., “Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism,” The American Journal of Pathology, vol. 178, no. 5, pp. 2205–2214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Noh, Y. O. Eun, Y. S. Ji et al., “Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-β1-induced renal injury,” American Journal of Physiology-Renal Physiology, vol. 297, no. 3, pp. F729–F738, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Gao, K. Aqie, J. Zhu et al., “MG132 ameliorates kidney lesions by inhibiting the degradation of smad7 in streptozotocin-induced diabetic nephropathy,” Journal of Diabetes Research, vol. 2014, Article ID 918396, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. W. Huang, C. Yang, Q. Nan et al., “The proteasome inhibitor, MG132, attenuates diabetic nephropathy by inhibiting SnoN degradation in vivo and in vitro,” BioMed Research International, vol. 2014, Article ID 684765, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Van Beneden, C. Geers, M. Pauwels et al., “Valproic acid attenuates proteinuria and kidney injury,” Journal of the American Society of Nephrology, vol. 22, no. 10, pp. 1863–1875, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. T.-S. Ha, E.-J. Hong, and G.-D. Han, “Diabetic conditions downregulate the expression of CD2AP in podocytes via PI3-K/Akt signalling,” Diabetes/Metabolism Research and Reviews, vol. 31, no. 1, pp. 50–60, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Kitada and D. Koya, “Renal protective effects of resveratrol,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 568093, 7 pages, 2013. View at Publisher · View at Google Scholar